Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer

Figure 1

Plasma levels of HMGB1 during peptide vaccination. Plasma HMGB1 levels of pre- and post-1st cycle vaccination samples of the total 39 cases (a), the 21 serous-type cases (b), and the 18 non-serous-type cases (c) are shown. ns: Not significant.

(a)

(b)

(c)